SH3PXD2B Activators
SH3PXD2B activators are a specialized set of chemical compounds that indirectly but effectively enhance the functional activity of SH3PXD2B through distinct signaling mechanisms. Forskolin, by increasing intracellular cAMP, and cyclic ADP-ribose, through boosting calcium signaling, trigger protein kinases such as PKA and calcium-dependent kinases, leading to the phosphorylation of associated proteins. This post-translational modification facilitates SH3PXD2B's role in processes like cellular adhesion, migration, and vesicle trafficking. Ionomycin further supports this by elevating calcium levels to activate pathways in which SH3PXD2B is implicated, particularly those governing cytoskeletal organization. Similarly, protein kinase C is activated by Phorbol 12-myristate 13-acetate (PMA), which then phosphorylates interactors of SH3PXD2B, enhancing its activity in invadopodia formation crucial for cell motility. Epigallocatechin gallate (EGCG) adds to this modulation by inhibiting competitive kinase signaling, thus relieving inhibitory pathways and accentuating SH3PXD2B's role in actin dynamics.
Furthermore, the biochemical landscape influencing SH3PXD2B is also shaped by compounds such as LY294002 and U0126, which inhibit PI3K and MEK1/2 respectively, thus altering downstream signaling cascades like Akt and MAPK pathways that intersect with SH3PXD2B's function in migration and invasion. SB203580, targeting p38 MAPK, shifts the signaling equilibrium, potentially enhancing SH3PXD2B's activity by modifying the cellular stress response, which is closely linked to cytoskeletal dynamics. Sphingosine-1-phosphate (S1P) and Thapsigargin modulate lipid and calcium signaling, respectively, further influencing SH3PXD2B's role in cellular adhesion and motility. Genistein, by inhibiting tyrosine kinase activity, reduces competitive signaling, facilitating SH3PXD2B-mediated cytoskeletal organization. Lastly, Staurosporine, despite its broad kinase inhibition spectrum, may lead to selective activation of SH3PXD2B pathways by reducing the activity of kinases that suppress SH3PXD2B-dependent processes.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Forskolin raises intracellular cAMP levels which can activate PKA. Activated PKA can phosphorylate downstream targets that may include structural proteins and regulators that interact with SH3PXD2B, leading to its functional activation in cellular adhesion processes. | ||||||
Ionomycin | 56092-82-1 | sc-3592 sc-3592A | 1 mg 5 mg | $78.00 $270.00 | 80 | |
Ionomycin is a calcium ionophore that increases intracellular calcium concentrations, which can activate calcium-dependent protein kinases that interact with SH3PXD2B and facilitate its role in cytoskeletal organization. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
PMA activates protein kinase C (PKC) which is involved in a multitude of cellular processes including the regulation of cytoskeletal dynamics. PKC activation can lead to the phosphorylation of proteins that associate with SH3PXD2B, enhancing its activity in cell motility and invadopodia formation. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $43.00 $73.00 $126.00 $243.00 $530.00 $1259.00 | 11 | |
EGCG acts as a kinase inhibitor, potentially reducing competitive signaling pathways and allowing SH3PXD2B-mediated pathways to become more dominant, specifically in actin cytoskeleton remodeling and cellular adhesion. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor that can modify downstream signaling pathways, such as Akt signaling, which may intersect with SH3PXD2B pathways to regulate cellular migration and invasion. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a p38 MAPK inhibitor that might lead to an increased activity of SH3PXD2B by altering the cellular stress response, which in turn could affect the cytoskeletal dynamics and cell motility. | ||||||
D-erythro-Sphingosine-1-phosphate | 26993-30-6 | sc-201383 sc-201383D sc-201383A sc-201383B sc-201383C | 1 mg 2 mg 5 mg 10 mg 25 mg | $165.00 $322.00 $570.00 $907.00 $1727.00 | 7 | |
S1P is a bioactive lipid that activates S1P receptors, influencing actin cytoskeletal reorganization and cellular adhesion. These changes in the cellular architecture can indirectly enhance the activity of SH3PXD2B in cellular processes like phagocytosis. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $136.00 $446.00 | 114 | |
Thapsigargin disrupts calcium homeostasis by blocking the sarcoplasmic/endoplasmic reticulum Ca2+ ATPase (SERCA), potentially affecting calcium-dependent signaling pathways associated with SH3PXD2B's role in cellular motility and adhesion. | ||||||
Genistein | 446-72-0 | sc-3515 sc-3515A sc-3515B sc-3515C sc-3515D sc-3515E sc-3515F | 100 mg 500 mg 1 g 5 g 10 g 25 g 100 g | $45.00 $164.00 $200.00 $402.00 $575.00 $981.00 $2031.00 | 46 | |
Genistein is a tyrosine kinase inhibitor which could enhance SH3PXD2B activity by reducing competition from tyrosine kinase signaling, thus indirectly promoting SH3PXD2B-mediated cytoskeletal organization and cell motility. | ||||||
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine is a broad-spectrum protein kinase inhibitor which can modify various signaling pathways. In particular, it may selectively enhance SH3PXD2B's role in the formation of invadopodia by modulating the activity of kinases that normally suppress this process. | ||||||